HiberCell Acquires Genuity Science, Inc.

H.I.G. Capital Acquires Celerion

November 3, 2022

Healthcare Services

H.I.G. Capital (through an affiliate) completed the acquisition of Celerion Holdings, Inc., a global clinical research organization headquartered in Lincoln, Nebraska. Celerion provides end-to-end early-stage clinical trial and bioanalytical services to pharmaceutical and biotechnology clients; H.I.G. said the investment expands its pharma services platform and supports Celerion's growth plans.

OncoCyte Corporation Acquires Insight Genetics

January 10, 2020

Healthcare Services

OncoCyte Corporation agreed to acquire all outstanding capital stock of Insight Genetics, a privately held molecular diagnostics company, for approximately $12 million in cash and stock plus potential contingent payments. The acquisition adds Insight Genetics' IM Score immuno-oncology diagnostic test and a pharma-trial–capable CLIA/CAP lab to OncoCyte's portfolio to expand its capabilities in oncology diagnostics and pharma services.

H.I.G. Capital Acquires Taconic Biosciences

February 7, 2019

Healthcare Services

H.I.G. Capital, through an affiliate, has completed the acquisition of Taconic Biosciences, a global provider of genetically engineered research models and related services. The private equity investment will partner with Taconic's management to support geographic expansion, broaden product and service offerings, and accelerate M&A-driven growth.

CellCarta Acquires Biogazelle

December 14, 2021

Biotechnology

CellCarta has acquired Biogazelle, a Ghent-based leader in digital PCR (dPCR), qPCR and RNASeq assay development, to strengthen and expand its genomic capabilities. The acquisition creates a Center of Excellence for complex genomic biomarker assay development within CellCarta and broadens its service offering for pharmaceutical and biotech clients across discovery and clinical stages.

Essex Partners Forms SkinGenuity LLC to Acquire SkinGenuity Product Line from SkinGen, USA

June 20, 2023

Consumer Products

Essex Partners, an independent sponsor affiliate of Essex Capital Group, formed SkinGenuity, LLC to acquire the SkinGenuity line of skincare products from SkinGen, USA. The product line uses bio‑engineered growth factors and DNA repair enzymes for vaginal regeneration, hair rejuvenation and other skincare applications; Essex intends to commercialize and expand distribution domestically and internationally.

Vizgen Acquires Ultivue (Merger to Form Combined Spatial Biology Company)

October 9, 2024

Biotechnology

Vizgen and Ultivue have merged to create a single spatial biology company that combines Vizgen’s MERFISH single-cell spatial genomics platform with Ultivue’s InSituPlex assays and STARVUE proteomic/AI capabilities. Rob Carson (former CEO of Ultivue) will serve as President and CEO of the combined Vizgen, and the transaction was completed alongside Vizgen’s Series D financing backed by investors including ARCH Venture Partners, Northpond Ventures and Tao Capital Partners.